• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

CD158K/KIR3DL2 Polyklonaler Antikörper

CD158K/KIR3DL2 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

Konjugation

Unkonjugiert

Kat-Nr. : 33010-1-PBS

Synonyme

KIR3DL2, CD158K, MHC class I NK cell receptor, NKAT 4, NKAT4

Filter:
  • Western Blot (WB) analysis of various lysates using CD158K/KIR3DL2 Polyclonal antibody (33010-1-AP)

    WB analysis using 33010-1-AP (same clone as 33010-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 33010-1-AP (CD158K/KIR3DL2 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 33010-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

33010-1-PBS bindet in CD158K/KIR3DL2 und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen CD158K/KIR3DL2 fusion protein Eg4355
Vollständiger Name killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2
Berechnetes Molekulargewicht50 kDa
Beobachtetes Molekulargewicht 50-60 kda
GenBank-ZugangsnummerNM_006737.4
Gene symbol KIR3DL2
Gene ID (NCBI) 3812
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

KIR3DL2, also known as CD158k, is an inhibitory receptor expressed by natural killer (NK) cells and a subset of CD8+ T cells. It plays a role in immune regulation by binding to HLA class I molecules, specifically HLA-A3 and HLA-A11, in a peptide-dependent fashion. KIR3DL2 can also function as an innate immune receptor for delivering CpG DNA to TLR9 in NK cells, highlighting its role in both adaptive and innate immunity. This protein is primarily expressed on the cell surface, particularly in NK cells and certain T cells. It has been implicated in various diseases, particularly in the context of hematological malignancies and autoimmune diseases. Aberrant expression of KIR3DL2 has been observed in neoplastic cells in transformed mycosis fungoides and Sézary syndrome, suggesting its potential as a therapeutic target in primary cutaneous anaplastic large-cell lymphoma (pcALCL).